A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

Diabetes Care

Volumn 28, Issue 7, 2005, Pages 1547-1554

  Goldberg, Ronald B ^a   Kendall, David M ^b   Deeg, Mark A ^c   Buse, John B ^d   Zagar, Anthony J ^e   Pinaire, Jane A ^e   Tan, Meng H ^e   Khan, Mehmood A ^f   Perez, Alfonso T ^f   Jacober, Scott J ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b INTERNATIONAL DIABETES CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e ELI LILLY AND COMPANY   (United States)

^f TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFECT; DYSLIPIDEMIA; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PARTICLE SIZE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 21544466158     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.7.1547     Document Type: Article

References (49)

1. Haffner SM, D'Agostino R Jr, Mykkanen L, Tracy R, Howard B, Rewers M, Selby J, Savage PJ, Saad MF: Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22:562-568, 1999
2. Nesto RW: Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 116:11S-22S, 2004
3. Hsueh WA, Lyon CJ, Quinones MJ: Insulin resistance and the endothelium. Am J Med 1 17:109-117, 2004
4. Siegel RD, Cupples A, Schaefer EJ, Wilson PW: Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 45:1267-1272, 1996
5. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 106:453-458, 2000
6. Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 27:1496-1504, 2004
7. Garvey WT, Kwon S, Zheng D, Shaughnessy S, Wallace P, Hutto A, Pugh K, Jenkins AJ, Klein RL, Liao Y: Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52:453-462, 2003
8. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79:8-15, 1989
9. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389, 1994
10. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 333:1301-1307, 1995
11. Ginsberg HN: Hypertriglyceridemia: new insights and new approaches to pharmacologic therapy. Am J Cardiol 87:1174-1180, 2001
12. American Diabetes Association: Dyslipidemia management in adults with diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S68-S71, 2004
13. King AB: A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones (Letter). Diabetes Care 23:557, 2000
14. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, Martin J: Effects of piogliiazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 24:378-396, 2002
15. Khan MA, St Peter JV, Xoe JL: A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 25:708-711, 2002
16. LaCivita KA, Villarreal G: Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Cure Med Res Opin 18:363-370, 2002
17. Olansky L, Marchetti A, Lau H: Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther 25:B64-B80, 2003
18. van Wijk JPH, de Koning EJP, Martens EP, Rabelink TJ: Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 23:1744-1749, 2003
19. Buse JB, Tan MH, Prince MJ, Erickson PP: The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 6:133-156, 2004
20. Derosa G, Cicero AFG, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN: Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 26: 744-754, 2004
21. Gegick CG Altheimer MD: Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors. Curr Med Res Opin 20: 919-930, 2004
22. Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H: Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin 20:215-223, 2004
23. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes. Diabetes Care 23:1605-1611, 2000
24. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A: Once-and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 24:308-315, 2001
25. Matthews DR, Hosker JB, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
26. Searle SR: Linear Models for Unbalanced Data. New York, John Wiley & Sons, 1987
27. Gallo PP: Practical issues in linear models analyses in multicenter clinical trials. Biopharm Rep 6:2-9, 1998
28. Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE: The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes, mellitus. Coron Artery Dis 12: 413-423, 2001
29. Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jimenez F, Hardin PA, Konkoy CS, Tan MH: A randomized, double-blinded, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 25:1074-1095, 2003
30. Patel J, Anderson RJ, Rappaport EB: Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1:165-172, 1999
31. Nolan JJ, Jones NP, Patwardhan R, Deacon LF: Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 17:287-294, 2000
32. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI: Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type 11 diabetes. Diabetologia 43:278-284, 2000
33. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 86:280-288, 2001
34. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316:823-828, 1998
35. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA 285:2486-2497, 2001
36. Grundy SM, Cleeman JI, Bairey Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: A summary of implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Arterioscler Thromb Vasc Biol 24:1329-1330, 2004
37. Rubins HB, Robins SJ, Collins D, Eye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low HDL-cholesterol. N Engl J Med 341:410-418, 1999
38. Zarich SW: Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors. Rev Cardiovasc Med 4 (Suppl. 6):S19-S28, 2003
39. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 279:1955-1961, 1998
40. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM: Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 92:141-146, 1993
41. Lahdenpera S, Syvanne M, Kahri J, Taskinen MR: Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 39:453-461, 1996
42. Taskinen MR: Diabetic clyslipidemia. Atheroscler Suppl 3:47-51, 2002
43. Freed MI, Ratner R, Marcovina SM, Kreider MM, Biswas N, Cohen BR, Brunzell JD, Rosiglitazone Study 108 investigators: Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 90:947-952, 2002
44. Bell DS: Dyslipidemia in type 2 diabetes and the effect of thiazolidinediones. Endocrinologist 13:496-504, 2003
45. Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Toben JA, Simvastatin/Thiazolidinedione Study Group. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellilus: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 26:379-389, 2004
46. CARE Foundation: CARE today [article online], 2004. Available from http://www. aspirus.org/heart_institute/newsletters/CaRETodayWinter04.pdf. Accessed 30 April 2005
47. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A: The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 27:1647-1653, 2004
48. CME on diabetes [article online], 2004. Available from http://www.cmeondiabetes. com/pub/shifting.the.paradigm.from.step wise.to.early.combination.therapy.php. Accessed 8 August 2004
49. Sobel BE, Frye R, Detre KM: Burgeoning dilemmas in the management of diabetes and cardiovascular disease. Rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 107:636-642, 2003